SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven gets 4 patent approvals in key markets

27 May 2011 Evaluate

Suven Life Sciences has received four product patents from different countries for its new chemical entities (NCEs) which could be used in treating various central nervous system disorders. he four product patents, one from New Zealand, one from Australia, one from Korea and one from Europe are valid through 2025. With these new patents, the company now has eight patents from Europe, ten from New Zealand, nine from Australia and three from Korea for the NCEs

The company has received the approval for molecules which could be used in the treatment of CNS disorders like Parkinsons, Alzheimers and schizophrenia. Products out of these inventions may be out-licensed at various phases of clinical research like at phase I or phase II

crackcrack

Suven Life Sciences Share Price

224.15 3.45 (1.56%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×